Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?

Table 1 Randomised multicentre clinical trials with skin cancer as the primary endpoint

Study	Patient number	Primary endpoint	Primary endpoint result	Comments
Australian study	Control: 47 (23)^a	Number of new NMSC/patient/year	Significant	A significant decrease in SCC, but not BCC
Australian study	mTORi: 39 (19)	Number of new NMSC/patient/year	Significant	A significant decrease in SCC, but not BCC
TUMORAPA	Control: 56 (12)	Survival free of new SCC	Significant	patients with 1 prior SCC benefited significantly; those with multiple previous SCC did not significantly benefit
TUMORAPA	mTORi: 64 (22)	Survival free of new SCC	Significant
RESCUE	Control: 81 (14)	Risk of new SCC	Not significant	HR improved in 1-year analysis, but did not after 2-year follow-up
RESCUE	mTORi: 74 (39)	Risk of new SCC	Not significant

SCC squamous cell carcinoma, BCC basal cell carcinoma, NMSC non-melanoma skin cancer, Control patients not receiving mTOR inhibitors, mTORi mTOR inhibitor group, HR hazard ratio.
^aNumber in parentheses represents patients dropping out of study. For the definition of a dropout and number of patients that completed the study according to the protocol, see the individual publications.

ISSN: 2047-1440